PEGylated IL2 and tumor-targeted radiotherapy augment CD8+ T cell-mediated anti-tumor response to anti-PD-1 in head and neck squamous cell carcinoma. (PubMed, Theranostics) - Sep 9, 2026 - "We report a phase II clinical trial evaluating tumor-targeted radiotherapy, pegIL2 (BEMPEG), and ICI (pembrolizumab) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), and combination pre-clinically of radiopharmaceutical therapy (RPT), pegIL2, and ICI in HNSCC...RPT (90Y-NM600) was evaluated in combination with pegIL2 and anti-PD-L1 in murine MOC2 and SCC7 HNSCC models...Preclinically, tumor-targeted RPT and pegIL2 augment response to ICI through CD8+ T cell memory acquisition and regulatory monocyte suppression. This study provides preclinical and clinical insight for HNSCC treatment."
IO biomarker • Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD8 • IL2 • STING • TNFA
|
|
A Mario Q Marcondes; Adam R Burr; Alexander A Pieper; Amber Bates; Caroline P Kerr; Hari Menon; Irene M Ong; Jamey Weichert; Jens C Eickhoff; Justine Y Bruce; Lauren Zebertavage; Mary A Tagliaferri; Paul A Clark; Paul M Harari; Paul M Sondel; Reinier Hernandez; Sarah Seiter; Tabassum A Kennedy; Tracy J Berg; Willem W Overwijk; Won Jong Jin; Yujuan Wang; Zachary S Morris
|